MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only.
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval ...
Health doesn't only begin in hospitals and clinics. It can often start wherever people gather and trust one another. That's why Novartis and the Novartis Foundation work alongside local partners to ...
ノバルティスについて 患者さんと一般の方向け 医療関係者向け情報 研究開発 ESG（環境・社会・ガバナンス） ニュース 採用情報 お問い合わせ ノバルティス社員の安否確認窓口 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results